1. Multidrug Resistence Prevalence in COVID Area.
- Author
-
Aurilio, Caterina, Sansone, Pasquale, Paladini, Antonella, Barbarisi, Manlio, Coppolino, Francesco, Pota, Vincenzo, and Pace, Maria Caterina
- Subjects
COVID-19 ,COVID-19 pandemic ,SARS-CoV-2 ,VIRUS diseases ,PANDEMICS ,RESPIRATORY infections ,MIDDLE East respiratory syndrome - Abstract
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is often complicated by severe acute respiratory syndrome. The new coronavirus outbreak started in China in December 2019 and rapidly spread around the world. The high diffusibility of the virus was the reason for the outbreak of the pandemic viral disease, reaching more than 100 million infected people globally by the first three months of 2021. In the various treatments used up to now, the use of antimicrobial drugs for the management, especially of bacterial co-infections, is very frequent in patients admitted to intensive care. In addition, critically ill patients with SARS-CoV-2 infection are subjected to prolonged mechanical ventilation and other therapeutic procedures often responsible for developing hospital co-infections due to multidrug-resistant bacteria. Co-infections contribute to the increase in the morbidity–mortality of viral respiratory infections. We performed this study to review the recent articles published on the antibiotic bacterial resistance and viruses to predict risk factors of coronavirus disease 2019 and to assess the multidrug resistance in patients hospitalized in the COVID-19 area. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF